Top stories in gastroenterology: increased adenoma detection, colon cancer screening safe for IBD patients

Among the top stories in gastroenterology is new research showing that methylene blue dye delivered via oral tablet could increase adenoma detection rate and could detect colorectal cancer early. Patients with inflammatory bowel disease and no additional high-risk factors carried a very low risk for developing advanced colorectal neoplasia. Other stories include a new drug that could protect celiac patients from gluten exposure, 10 recent advances in Crohn’s and colitis, and adverse opioid-related events among patients who underwent surgical or endoscopic procedures.

Oral blue dye tablet increases adenoma detection in colonoscopy

Methylene blue dye delivered through an oral tablet has the potential to increase adenoma detection rates and could assist in the early detection of colorectal cancer, according to research released ahead of Digestive Disease Week. Read More.

Less frequent colon cancer screening may be safe in some IBD patients

Research published in Gut showed that patients with inflammatory bowel disease and no additional high-risk factors who had consecutive negative colonoscopies carried a very low risk for developing advanced colorectal neoplasia. Read More.

New drug may protect celiac patients from inadvertent gluten exposure

An experimental biologic drug showed promise for reducing symptoms and inflammation in patients with celiac disease following gluten exposure, according to data from a phase 2 proof-of-concept study released in advance of DDW 2018. Read More.

World IBD Day: 10 recent advances in Crohn’s and colitis research

Coordinated by the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA), World IBD Day is a global initiative intended to raise awareness of inflammatory bowel disease, which affects an estimated 10 million people worldwide, according to the organization's website. Read More.

Opioid-related adverse events common after surgical, endoscopic procedures

More than 10% of patients who underwent a surgical or endoscopic procedure experienced an opioid-related adverse drug event, and these were associated with worse outcomes and higher costs, according to new data published in JAMA Surgery. Read More.